Mislav Glibo1, Alan Serman2, Valentina Karin-Kujundzic3, Ivanka Bekavac Vlatkovic2, Berivoj Miskovic2, Semir Vranic4, Ljiljana Serman3. 1. Department of Biology, School of Medicine, University of Zagreb, Zagreb, Croatia. 2. Centre of Excellence in Reproductive and Regenerative Medicine, University of Zagreb School of Medicine, Zagreb, Croatia; Department of Obstetrics and Gynecology, School of Medicine, University of Zagreb, Zagreb, Croatia; Clinic of Obstetrics and Gynecology, Clinical Hospital "Sveti Duh", Zagreb, Croatia. 3. Department of Biology, School of Medicine, University of Zagreb, Zagreb, Croatia; Centre of Excellence in Reproductive and Regenerative Medicine, University of Zagreb School of Medicine, Zagreb, Croatia. 4. College of Medicine, QU Health, Qatar University, Doha, Qatar.
Abstract
Glycogen synthase kinase 3 (GSK3) is a monomeric serine-threonine kinase discovered in 1980 in a rat skeletal muscle. It has been involved in various cellular processes including embryogenesis, immune response, inflammation, apoptosis, autophagy, wound healing, neurodegeneration, and carcinogenesis. GSK3 exists in two different isoforms, GSK3α and GSK3β, both containing seven antiparallel beta-plates, a short linking part and an alpha helix, but coded by different genes and variously expressed in human tissues. In the current review, we comprehensively appraise the current literature on the role of GSK3 in various cancers with emphasis on ovarian carcinoma. Our findings indicate that the role of GSK3 in ovarian cancer development cannot be decisively determined as the currently available data support both prooncogenic and tumor-suppressive effects. Likewise, the clinical impact of GSK3 expression on ovarian cancer patients and its potential therapeutic implications are also limited. Further studies are needed to fully elucidate the pathophysiological and clinical implications of GSK3 activity in ovarian cancer.
Glycogen synthase kinase 3 (an class="Gene">GSK3) is a monomeric an class="Chemical">serine-threonine kinase discovered in 1980 in arat skeletal muscle. It has been involved in various cellular processes including embryogenesis, immune response, inflammation, apoptosis, autophagy, wound healing, neurodegeneration, and carcinogenesis. GSK3 exists in two different isoforms, GSK3α and GSK3β, both containing seven antiparallel beta-plates, a short linking part and an alpha helix, but coded by different genes and variously expressed in human tissues. In the current review, we comprehensively appraise the current literature on the role of GSK3 in various cancers with emphasis on ovarian carcinoma. Our findings indicate that the role of GSK3 in ovarian cancer development cannot be decisively determined as the currently available data support both prooncogenic and tumor-suppressive effects. Likewise, the clinical impact of GSK3 expression on ovarian cancerpatients and its potential therapeutic implications are also limited. Further studies are needed to fully elucidate the pathophysiological and clinical implications of GSK3 activity in ovarian cancer.
Authors: Lucy Liu; Sangkil Nam; Yan Tian; Fan Yang; Jun Wu; Yan Wang; Anna Scuto; Panos Polychronopoulos; Prokopios Magiatis; Leandros Skaltsounis; Richard Jove Journal: Cancer Res Date: 2011-05-24 Impact factor: 12.701
Authors: E Kassi; T G Sourlingas; M Spiliotaki; Z Papoutsi; H Pratsinis; N Aligiannis; P Moutsatsou Journal: Cancer Invest Date: 2009-08 Impact factor: 2.176
Authors: Keith M Jacobs; Sandeep R Bhave; Daniel J Ferraro; Jerry J Jaboin; Dennis E Hallahan; Dinesh Thotala Journal: Int J Cell Biol Date: 2012-05-21
Authors: K Rask; A Nilsson; M Brännström; P Carlsson; P Hellberg; P-O Janson; L Hedin; K Sundfeldt Journal: Br J Cancer Date: 2003-10-06 Impact factor: 7.640